Table 3: Predictors of response to niacin ER (500 mg dose).

High responder1
( )
Low responder2
( )
Crude OR (95% CI)3Adjusted OR (95% CI)3,4
(%) (%)

Age (years, continuous)0.10 (0.97–1.02)1.0 (0.97–1.03)
Gender
 Female39 (32.5%)53 (29.1%)1.01.0
 Male81 (67.5%)129 (70.9%)0.85 (0.52–1.40)0.79 (0.25–2.51)
HDL-C mg/dL (males only)
 ≥4049 (40.8%)111 (61.0%)1.01.0
 40 71 (59.2%)71 (39.0%)2.27 (1.42–3.63)5.18 (2.36–11.39)
HDL-C mg/dL (females only)
 ≥5087 (72.5%)155 (85.2%)1.01.0
 <50 33 (27.5%)27 (14.8%)2.18 (1.23–3.86)5.40 (1.84–15.79)
LDL-C mg/dL
 <13069 (57.5%)103 (56.6%)1.01.0
 ≥130 51 (42.5%)79 (43.4%)0.96 (0.61–1.54)1.23 (0.54–2.77)
TG mg/dL
 <15032 (26.7%)71 (39.0%)1.01.0
 ≥15088 (73.3%)111 (61.0%)1.76 (1.06–2.91)1.38 (0.76–2.50)
TC mg/dL
 <20062 (51.7%)85 (46.7%)1.01.0
 ≥20058 (48.3%)97 (53.3%)0.82 (0.52–1.30)1.0 (0.42–2.34)
Diabetes
 No82 (68.3%)138 (75.8%)1.01.0
 Yes 38 (31.7%)44 (24.2%)1.45 (0.87–2.43)1.41 (0.78–2.52)
Stroke (within 6 months)
 No114 (95.0%)174 (95.6%)1.01.0
 Yes 6 (5.0%)8 (4.4%)1.15 (0.39–3.39)0.69 (0.19–2.49)
Hypertension (within 6 months)
 No108 (90.0%)171 (94.0%)1.01.0
 Yes 12 (10.0%)11 (6.0%)1.73 (0.74–4.05)1.91 (0.71–5.15)
Ischemic heart disease (within 6 months)
 No97 (80.8%)147 (80.8%)1.01.0
 Yes 23 (19.2%)35 (19.2%)1.0 (0.56–1.79)0.91 (0.44–1.87)
Statin use during baseline
 No50 (41.7%)63 (34.6%)1.01.0
 Yes70 (58.3%)119 (65.4%)0.74 (0.46–1.19)0.69 (0.37–1.31)
Fibric acid use during Baseline
 No10 (8.3%)22 (12.1%)1.01.0
 Yes 110 (91.7%)160 (87.9%)1.51 (0.69–3.32)1.60 (0.69–3.75)

Definition of lipids: HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; TG: triglycerides; TC: total cholesterol.
1High responder: HDL-C effect > 15%.
2Low responder: HDL-C effect < 5%.
3Outcome is high responder.
4Adjusted model includes all variables listed in the table.